Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 23, 2025Frontiers in OncologyOpen Access

SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance

View Full Paper
Ask AI
Bookmark
Share

Authors

KZKaiyu ZhouYLYuewen LiWWWeifang Wang

Discussion

Loading...

Member takes

Overview

Review highlights how SLFN11 predicts therapeutic responses to DNA-damaging agents in cancer, implying strategies for precision treatment.

Key Points

  • SLFN11 acts as a biomarker for predicting responses to DNA-damaging agents in cancer treatment.
  • Data from studies indicate SLFN11 expression correlates with sensitivity to various DNA-targeted drugs.
  • Therapeutic strategies leveraging SLFN11 could enhance efficacy and overcome drug resistance.
  • Understanding SLFN11's role advances precision cancer therapy by optimizing treatment approaches.

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/689a061be6551bb0af8cd9d0https://doi.org/10.3389/fonc.2025.1582738
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immunohistochemical Evaluation of Schlafen 11 (SLFN11) Expression in Cancer in the Search of Biomarker-Informed Treatment Targets2024 · 6 citations
  2. 2Data from Schlafen 11 (SLFN11) kills cancer cells undergoing unscheduled re-replication2024
  3. 3SLFN11, far from being limited to responding to cancer DNA damage2025
  4. 4Integrated Bioinformatic and Experimental Analysis of SLFN11 Expression and Clinical Significance in Locally Advanced Rectal Cancer2026
  5. 5SLFN11 Enhances PARPi Sensitivity in Ovarian Cancer via Ubiquitin-Mediated Stabilization2026